Jul. 9 at 11:38 AM
$EDAP this company has what should be the “standard of care” for prostate cancer, and BPH. I have predicted for years that they would be bought out.
However, the adoption rate has been very slow. Last year I called the company and asked for the list of doctors in Illinois who are using this. There was only ONE.
They are still losing money, and on the q1 CC the CEO mentioned the need for a near term CAPITAL RAISE.
So be aware of likely share dilution or debt financing in near future.
